ijms-logo

Journal Browser

Journal Browser

Myeloid-Derived Suppressor Cells in Cancer

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: closed (31 January 2024) | Viewed by 2073

Special Issue Editor


E-Mail Website
Guest Editor
Department of Laboratory Medicine, Karolinska Institutet, 14152 Huddinge, Sweden
Interests: myeloid derived suppressor cells (MDSCs); tumor-induced Immunosuppression

Special Issue Information

Dear Colleagues,

During their development and progression, tumors acquire specific properties that enable them to evade immune responses, creating conditions that suppress the antitumor immune response. Over the past decade, the generation and expansion of myeloid-derived suppressor cells (MDSCs) have emerged as a critical mechanism for cancer-induced immunosuppression. MDSCs are a heterogeneous group of immature myeloid cells that induce potent immunosuppression by producing various immune-inhibitory cytokines, enzymes, and chemically reactive molecules containing oxygen and nitrogen. Extensive clinical and experimental studies have shown that MDSC levels correlate with tumor burden, stage, and short-term survival. Consequently, MDSCs are now considered major challenges in cancer immunotherapies, and targeting them could be a highly valuable strategy to enhance the effectiveness of chemotherapeutic and immunotherapeutic approaches.

Experimental tumor models have contributed significantly to a better understanding of the underlying mechanisms involved in the development, homing, and functionality of MDSCs in tumors. They have also been instrumental in testing anti-MDSC therapies in vivo. However, the precise role of tumor cells, host cells, and microbiota in generating and expanding these cells remains elusive.

Furthermore, information obtained from experimental tumors cannot be directly applied to patients with cancer because of the substantial heterogeneity of MDSCs across different cancer types. Additionally, the lack of specific biomarkers and a straightforward separation/characterization technique for human MDSCs has resulted in limited knowledge about tumor-infiltrating MDSCs in human cancers and their roles in tumor progression and metastasis.

This Special Issue, entitled "Myeloid-Derived Suppressor Cells in Cancer" aims to consider papers for publication that address the aforementioned challenges related to MDSCs in different cancers, as well as those exploring the biology of MDSCs and novel modalities that target these cells in cancer.

Dr. Manuchehr Abedi-Valugerdi
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • tumor
  • myeloid-derived suppressor cells (MDSCs)
  • immunosuppression
  • immune escape
  • myelopoiesis
  • G-MDSCs
  • M-MDSCs
  • biomarkers
  • tumor models
  • extramedullary hematopoiesis

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

24 pages, 5570 KiB  
Article
Tumor Cell-Associated IL-1α Affects Breast Cancer Progression and Metastasis in Mice through Manipulation of the Tumor Immune Microenvironment
by Mathumathi Krishnamohan, Irena Kaplanov, Sapir Maudi-Boker, Muhammad Yousef, Noy Machluf-Katz, Idan Cohen, Moshe Elkabets, Jaison Titus, Marina Bersudsky, Ron N. Apte, Elena Voronov and Alex Braiman
Int. J. Mol. Sci. 2024, 25(7), 3950; https://doi.org/10.3390/ijms25073950 - 2 Apr 2024
Cited by 1 | Viewed by 1743
Abstract
IL-1α is a dual function cytokine that affects inflammatory and immune responses and plays a pivotal role in cancer. The effects of intracellular IL-1α on the development of triple negative breast cancer (TNBC) in mice were assessed using the CRISPR/Cas9 system to suppress [...] Read more.
IL-1α is a dual function cytokine that affects inflammatory and immune responses and plays a pivotal role in cancer. The effects of intracellular IL-1α on the development of triple negative breast cancer (TNBC) in mice were assessed using the CRISPR/Cas9 system to suppress IL-1α expression in 4T1 breast cancer cells. Knockout of IL-1α in 4T1 cells modified expression of multiple genes, including downregulation of cytokines and chemokines involved in the recruitment of tumor-associated pro-inflammatory cells. Orthotopical injection of IL-1α knockout (KO) 4T1 cells into BALB/c mice led to a significant decrease in local tumor growth and lung metastases, compared to injection of wild-type 4T1 (4T1/WT) cells. Neutrophils and myeloid-derived suppressor cells were abundant in tumors developing after injection of 4T1/WT cells, whereas more antigen-presenting cells were observed in the tumor microenvironment after injection of IL-1α KO 4T1 cells. This switch correlated with increased infiltration of CD3+CD8+ and NKp46+cells. Engraftment of IL-1α knockout 4T1 cells into immunodeficient NOD.SCID mice resulted in more rapid tumor growth, with increased lung metastasis in comparison to engraftment of 4T1/WT cells. Our results suggest that tumor-associated IL-1α is involved in TNBC progression in mice by modulating the interplay between immunosuppressive pro-inflammatory cells vs. antigen-presenting and cytotoxic cells. Full article
(This article belongs to the Special Issue Myeloid-Derived Suppressor Cells in Cancer)
Show Figures

Figure 1

Back to TopTop